Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822070 | 0.85 | ADORA1 (0.41) | PDE4BPDE3APDE5AADORA1GRIA1 | |
| SCHEMBL6821479 | 0.84 | ADORA1 (0.38) | ADORA1GRIA1TP53KMT2ANPSR1 | |
| SCHEMBL6818407 | 0.83 | ADORA1 (0.45) | PDE4BPDE3APDE5AADORA1MAPK14 | |
| SCHEMBL6822088 | 0.81 | ADORA1 (0.48) | PDE4BPDE3APDE5AADORA1MAPK14 | |
| SCHEMBL6822254 | 0.79 | TP53 (0.42) | ADORA1TP53KMT2ASMN1; SMN2 | |
| SCHEMBL7039587 | 0.78 | ADORA1 (0.57) | PDE4BPDE3APDE5AADORA1MAPK14 | |
| SCHEMBL6822604 | 0.78 | PDE4B (0.51) | PDE4BPDE3APDE5AGRIA1MAPK14 | |
| SCHEMBL6825199 | 0.77 | CASR (0.41) | ADORA1MAPK14CASR | |
| SCHEMBL6821959 | 0.77 | ADORA1 (0.42) | ADORA1CASRPDE1APDE1BPDE1C | |
| SCHEMBL8193926 | 0.75 | ADORA1 (0.45) | PDE3APDE5AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | PDE4B 563/4885PDE3A 137/4885PDE5A 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.